- Research Plus
- Portfolios & Watchlists
- Charting
- Screening Tools
- Visual Tools
- Education Guides
- UK Shares
- Funds
- International Shares
- Gilts
- Currencies
- Commodities
- Company Diary
- Free Brochures
- ETF Centre
- Real Time
Puretech Health Plc (PRTCL)
128.00p
- Change Today: -0.010p
- 52 Week High: 173.60
- 52 Week Low: 101.60
- Currency: UK Pounds
- Shares Issued: 237.39m
- Volume: 129,631
- Market Cap: £303.86m
PRTCL Overview
PureTech Health plc (“PureTech Health”, “PureTech” or “the Company”) is a clinical-stage biotherapeutics
company dedicated to discovering, developing and commercializing highly differentiated medicines for
devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers,
lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders, among others.
Key Personnel
| Independent Non-Executive Director: | John LaMattina |
| Independent Non-Executive Director: | Michele Holcomb |
| Independent Non-Executive Director: | Kiran Mazumdar Shaw |
| Interim Chairman: | Sharon Barber-Lui |
| Non-Executive Dir: | H. Robert Horvitz, Robert Langer |
Contact Details
| Address: | 6 Tide St Ste 400, Boston, United States, MA, 02210 |
| Phone: | +1 617 482 2333 |
| Website: | http://www.puretechhealth.com |
Listings
| Overseas Listings: | LSE:PRTC |
| ISIN: | GB00BY2Z0H74 |
PRTCL Market Data
| Currency | UK Pounds |
| Share Price | 128.00p |
| Change Today | -0.010p |
| % Change | -0.78 % |
| 52 Week High | 173.60 |
| 52 Week Low | 101.60 |
| Volume | 129,631 |
| Shares Issued | 237.39m |
| Market Cap | £303.86m |
What The Brokers Say
| Strong Buy | 1 |
| Buy | 0 |
| Neutral | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 1 |
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.
You are here: research
Digital Look Ltd,
10 Lower Thames St,
London EC3R 6EN
10 Lower Thames St,
London EC3R 6EN